SANUWAVE Health, Inc.

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025. EDEN PRAIRIE, Minn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-cleared wound care products, is pleased to provide its financial results for the three months ended June 30, 2026. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Quarter ended June 30, 2026 Revenue for the three months ended June 30, 2026, totaled $9.7 million, an decrease of 3%, as compared to $10.1 million for the same period of 2025. Revenue for the three months ended June 30, 2026 was slightly above the high end of the revised guidance provided on June 16, 2026. 82 Ultramist ® systems were sold in Q2 2026 down from 116 in Q2 2025, and from 97 in Q1 2026. Ultramist ® applicator revenue increased by 13% to $7.3 million in Q2 2026, versus $6.4 million for the same quarter last year. Gross margin as a percentage of revenue amounted to 76.2% for the three months ended June 30, 2026, versus 78.1% for the same period last year. For the three months ended June 30, 2026, operating (loss) income totaled $(0.3) million, compared to $1.4 million in Q2 2025. Net loss for the second quarter of 2026 was $0.7 million. This compares to net income of $0.6 million in the second quarter of 2025. Adjusted EBITDA [1] for the three months ended June 30, 2026, was $1.2 million versus Adjusted EBITDA of $3.2 million for the same period last year. “2026 has been a challenging period for the advanced wound care market,” said Morgan Frank, CEO. “Despite this, Q2 was another all time record for Ultramist applicator unit volumes, which increased 13% sequentially from Q1 and 27% year on year. We take this to be a strong sign of ongoing demand for and confidence in the Ultramist system as a treatment modality for complex and non-healing wounds. As previously discussed, system sales were negatively impacted in the quarter both by ongoing stress in our customer base from CMS reimbursement changes and recoupments around allografts and by the emergence of a significant market for used Ultramist systems, which led to lower than expected sales by the Company. As a result, applicator sales accounted for approximately 75% of revenues in the quarter, a number above our target range of 60-65%. The silver lining on that seems to be that demand for systems during the quarter remained fairly robust if one includes our estimation of used sales on top of those sold by the Company. Moving on to the CMS proposed rule for 2027 97610 reimbursement announced this July, obviously, this is neither what we were hoping for nor what we expected, especially in light of having just had a 14% increase in our proposed reimbursement rate in the HOPD setting come out a couple of weeks prior. While Sanuwave wholeheartedly supports CMS’s goal of accurate, data driven payment, we have some material disagreements with the methodology, process, and assumptions utilized by CMS in their proposed rule for 2027 and, as one might expect, will be active in the comment period to seek reconsideration before a final rule is issued. Our goal in this comment period will be to ensure that the data that drives this decision is both accurate and complete and that it reflects the full practitioner costs (and the systemic benefits) of providing treatment under 97610, which is, of course, the intent of these rules. We believe that we have a strong case to make and, with the support of a great many customers and academic institutions and thought leaders who have reached out with gracious offers to help, we plan to make it vigorously.” Certain percentages presented in this earnings release are calculated from the underlying whole-dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes. Financial Outlook Owing to market conditions including the Medicare reimbursement developments discussed above, Sanuwave is withdrawing its previously issued fiscal year 2026 guidance which should no longer be relied upon. The Company will not provide quarterly or annual guidance until there is greater clarity on these topics and expects to reassess after CMS publishes its final rule which is anticipated in the fourth quarter of 2026. As previously announced, a business update will occur via conference call on August 7, 2026 at 8:30 a.m. EST. Materials for the conference call are included on the Company’s website at . Telephone access to the call will be available by dialing the following numbers: Toll Free:1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR use the link for instant telephone access to the event. A replay will be made available through August 21, 2026: Toll-Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Access ID: 11162356 [1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information. About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions. Non-GAAP Financial Measures This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP. The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss), as a measure of financial performance or any other performance measure derived in accordance with U.S. GAAP, and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to U.S. GAAP measures, allows them to see the Company’s results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other U.S. GAAP measures. EBITDA, Adjusted EBITDA, Adjusted Gross Margin Percentage and Adjusted Operating Income have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under U.S. GAAP. For example, some of these limitations are that EBITDA and Adjusted EBITDA: Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments. Do not reflect all changes in our working capital needs. Do not reflect interest expense, or the amount necessary to service our outstanding debt. As presented in the U.S. GAAP to Non-GAAP Reconciliations section below, the Company’s non-GAAP financial measures exclude the impact of certain charges that contribute to our net income (loss). Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: reductions, clawbacks, or recoupments of CMS reimbursement for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; risks associated with regulatory oversight; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@sanuwave.com SELECTED FINANCIAL DATA FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025 Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2026 2025 2026 2025 Revenue $ 9,739 $ 10,054 $ 19,358 $ 19,387 Cost of Revenues 2,315 2,206 4,502 4,164 Gross Margin 7,424 7,848 14,856 15,223 Gross Margin % 76.2 % 78.1 % 76.7 % 78.5 % Total operating expenses 7,704 6,410 16,260 13,184 Operating (Loss) Income $ (280 ) $ 1,438 $ (1,404 ) $ 2,039 Total other expense (396 ) (887 ) (711 ) (7,606 ) Net (Loss) Income $ (682 ) $ 551 $ (2,121 ) $ (5,567 ) NON-GAAP ADJUSTED EBITDA Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2026 2025 2026 2025 Net (Loss) Income $ (682 ) $ 551 $ (2,121 ) $ (5,567 ) Non-GAAP Adjustments: Interest expense 518 1,939 1,064 3,848 Depreciation and amortization 1 313 226 607 493 EBITDA 149 2,716 (450 ) (1,226 ) Non-GAAP Adjustments for Adjusted EBITDA: Change in fair value of derivative liabilities - (990 ) - 3,911 Other non-cash or infrequent charges: Stock-based compensation 1,572 1,132 3,143 2,116 State & local sales tax 2 (532 ) 329 (194 ) 705 Sale of excess inventory - - (220 ) - Adjusted EBITDA $ 1,189 $ 3,188 $ 2,279 $ 5,506 1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation. This change had no effect on previously reported GAAP results. 2 The charges represent a non-recurring state and local sales tax expense related to the restatement of prior period financial statements. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2026 December 31, 2025 ASSETS Current Assets: Cash and cash equivalents $ 9,376 $ 11,959 Accounts receivable, net of allowance of $1,617 and $1,265, respectively 5,801 5,422 Inventory 7,070 5,934 Prepaid expenses and other current assets 954 1,312 Total Current Assets 23,201 24,627 Non-Current Assets: Property and equipment, net 2,255 1,972 Right of use assets, net 953 390 Intangible assets, net 2,887 3,026 Goodwill 7,260 7,260 Secured revolving credit facility debt issuance costs, net 49 68 Total Non-current Assets 13,404 12,716 Total Assets $ 36,605 $ 37,343 LIABILITIES Current Liabilities: Current portion of secured term loan, net of debt issuance costs $ 5,599 $ 5,638 Accounts payable 3,308 3,251 Accrued expenses 8,605 8,382 Current portion of operating lease liabilities 5 157 Current portion of contract liabilities 632 388 Accrued interest 17 24 Other 7 7 Total Current Liabilities 18,173 17,847 Non-current Liabilities: Secured term loan, net of current portion and debt issuance costs 12,922 15,667 Secured revolving credit facility 655 655 Operating lease liabilities, less current portion 1,525 854 Contract liabilities, less current portion 543 701 Total Non-current Liabilities 15,645 17,877 Total Liabilities $ 33,818 $ 35,724 STOCKHOLDERS’ EQUITY Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D designated, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025 $ - $ - Common stock, par value $0.001, 2,500,000,000 shares authorized; 8,602,309 and 8,588,876 issued and outstanding at June 30, 2026 and December 31, 2025, respectively 9 9 Additional paid-in capital 247,574 244,285 Accumulated deficit (244,806 ) (242,685 ) Accumulated other comprehensive income 10 10 Total Stockholders’ Equity 2,787 1,619 Total Liabilities and Stockholders’ Equity $ 36,605 $ 37,343 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Three Months Ended June 30, Six Months Ended June 30, 2026 2025 (As Restated) 2026 2025 (As Restated) Revenue $ 9,739 $ 10,054 $ 19,358 $ 19,387 Cost of Revenues 2,315 2,206 4,502 4,164 Gross Margin 7,424 7,848 14,856 15,223 Operating Expenses: General and administrative 4,902 4,368 10,152 9,211 Selling and marketing 1,923 1,674 4,322 3,205 Research and development 628 194 1,289 402 Depreciation and amortization 251 174 497 366 Total Operating Expenses 7,704 6,410 16,260 13,184 Operating (Loss) Income (280 ) 1,438 (1,404 ) 2,039 Other (Expense) Income: Interest expense (518 ) (1,939 ) (1,064 ) (3,848 ) Change in fair value of derivative liabilities - 990 — (3,911 ) Other expense (77 ) (27 ) (137 ) (28 ) Other income 199 89 490 181 Total Other Expense, net (396 ) (887 ) (711 ) (7,606 ) Net (Loss) Income Before Income Taxes (676 ) 551 (2,115 ) (5,567 ) Income tax expense 6 - 6 - Net (Loss) Income $ (682 ) $ 551 $ (2,121 ) $ (5,567 ) (Loss) Earnings per Share: Basic $ (0.08 ) $ 0.06 $ (0.25 ) $ (0.65 ) Diluted $ (0.08 ) $ (0.04 ) $ (0.25 ) $ (0.65 ) Weighted average shares outstanding Basic 8,601,198 8,561,737 8,596,148 8,554,706 Diluted 8,601,198 9,167,846 8,596,148 8,554,706 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (In thousands, except share data) Three Months Ended June 30, 2026 Common Stock Number of Shares Issued and Outstanding Par Value Additional Paid- in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balances as of March 31, 2026 8,594,209 $ 9 $ 245,943 $ (244,124 ) $ 10 $ 1,838 Stock-based compensation - - 1,403 - - 1,403 Stock options exercised 4,100 - 58 - - 58 Shares issued for services rendered 4,000 - 67 - - 67 Shares granted in lieu of board of director fees - - 102 - - 102 Net loss - - - (682 ) - (682 ) Balances as of June 30, 2026 8,602,309 $ 9 $ 247,574 $ (244,806 ) $ 10 $ 2,787 Three Months Ended June 30, 2025 Common Stock Number of Shares Issued and Outstanding Par Value Additional Paid- in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balances as of March 31, 2025 (As Restated) 8,548,473 $ 9 $ 239,786 $ (260,617 ) $ 10 $ (20,812 ) Stock-based compensation - - 1,132 - - 1,132 Stock options exercised 17,008 - 253 - - 253 Shares granted in lieu of board of director fees 2,524 - 77 - - 77 Net income (As Restated) - - - 551 - 551 Balances as of June 30, 2025 (As Restated) 8,568,005 $ 9 $ 241,248 $ (260,066 ) $ 10 $ (18,799 ) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (In thousands, except share data) Six Months Ended June 30, 2026 Common Stock Number of Shares Issued and Outstanding Par Value Additional Paid- in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balances as of December 31, 2025 8,588,876 $ 9 $ 244,285 $ (242,685 ) $ 10 $ 1,619 Stock-based compensation - 2,842 - - 2,842 Stock options exercised 5,433 - 77 - - 77 Shares issued for services rendered 8,000 - 164 - - 164 Shares granted in lieu of board of director fees - - 205 - - 205 Net loss - - - (2,121 ) - (2,121 ) Balances as of June 30, 2026 8,602,309 $ 9 $ 247,574 $ (244,806 ) $ 10 $ 2,787 Six Months Ended June 30, 2025 Common Stock Number of Shares Issued and Outstanding Par Value Additional Paid- in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balance as of December 31, 2024 (As Restated) 8,543,686 $ 9 $ 238,685 $ (254,499 ) $ 10 $ (15,795 ) Stock-based compensation 4,787 - 2,233 - - 2,233 Stock options exercised 17,008 - 253 - - 253 Shares granted in lieu of board of director fees 2,524 - 77 - - 77 Net loss (As Restated) - - - (5,567 ) - (5,567 ) Balances as of June 30, 2025 (As Restated) 8,568,005 $ 9 $ 241,248 $ (260,066 ) $ 10 $ (18,799 ) CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months Ended June 30, (in thousands) 2026 2025 (As Restated) Operating Activities: Net loss $ (2,121 ) $ (5,567 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities Stock-based compensation 3,143 2,106 Depreciation and amortization 607 388 Amortization of right-of-use leases 56 185 Provision for credit losses 379 131 Change in fair value of derivative liabilities - 3,911 Amortization of debt issuance and debt discounts 111 1,062 Write-off of inventory 69 - Loss on disposal of assets 18 - Proceeds from tenant improvement funds - 429 Changes in operating assets and liabilities Accounts receivable (757 ) (650 ) Inventory (1,205 ) (1,762 ) Prepaid expenses and other assets 385 (1,231 ) Accounts payable (133 ) 274 Accrued expenses and contract liabilities 370 200 Operating leases (100 ) - Net Cash Provided by (Used in) Operating Activities 822 (524 ) Investing Activities Purchase of property and equipment (357 ) (1,321 ) Deposits on property and equipment (35 ) - Investment in software development (213 ) - Net Cash Used in Investing Activities (606 ) (1,321 ) Financing Activities Proceeds from exercises of stock options 77 253 Repayment of principal secured term loan (2,875 ) - Payments of principal on finance leases - (149 ) Net Cash (Used in) Provided by Financing Activities (2,798 ) 104 Net Change in Cash During Period (2,583 ) (1,741 ) Cash at Beginning of Period 11,959 10,237 Cash at End of Period $ 9,376 $ 8,496 Supplemental Information: Cash paid for interest $ 828 $ 2,255 Cash paid for income taxes $ 51 $ - Non-cash Investing and Financing Activities: Right-of-use assets obtained in exchange for lease liabilities 619 430 Stock options granted in lieu of cash bonus 69 117 Purchases of property and equipment in accounts payable 191 - Capitalize interest into senior secured debt - 407 RSUs granted in exchange for services - 10

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year. “In the time since we had our Q1 call, we have seen material changes in the conditions in the capital equipment market for the Ultramist system,” said CEO Morgan Frank. “While March and April had shown signs of market improvement, May and the first part of June saw a reversal of these trends.” “Widespread clawbacks of CMS reimbursement for skin sub and allograft usage have been coming in far worse than many seem to have expected and this has been driving a number of wound care practices out of business. Some of these closures/liquidations appear to be resulting in used Ultramist systems for sale in the marketplace and this has had a significant cannibalization effect on the market for new systems.” “Sanuwave will always seek to do what’s best for the patients. As such, we will seek to lean in to qualify, train, and support new users in order to help ensure that they are able to provide the highest possible standard of care. We also believe that this is the best choice for the company: in the end, we’re in the applicator business, and patients, providers, and Sanuwave all win from increased levels of treatment.” “On a positive note, applicator volumes remain robust and the company is on pace for a record quarterly unit volume of consumables shipments in Q2. We remain optimistic about our pipeline and about our forward potential, but from a capital sales standpoint, this is going to be some near-term wood to chop.” About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions. Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: reductions, clawbacks, or recoupments of CMS reimbursement for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; any differences between updated guidance and final reported results following completion of the quarter; risks associated with regulatory oversight; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@sanuwave.com

Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue increased between 29% and 30% compared to Q4 2024. Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company. EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an increase of 29% to 30% over Q4 2024. This number is within the range of guidance given in the Company’s Q3 2025 earnings release issued on November 7, 2025. “We’re pleased to once more be on guidance and on track for Q4 and for full year 2025,” said CEO Morgan Frank. “As we discussed when releasing Q3, the second half of 2025 was a time of intense transition in the wound care space as reductions to reimbursement rates for skin-substitutes and allografts profoundly reshaped our market. Periods of such rearrangement are always times of opportunity and Sanuwave has been busy acquiring new partners, new sales channels, and adapting its business model for, while times may change, the fact of patients in need of advanced wound care does not. This space has been a bit of a loose ball drill, and loose balls go to the one who sees them first, moves fastest, and wants them most. I am proud to say that our team excelled in all these things this quarter and it feels good to end the year with another record quarter. We look forward to sharing more about how we are positioning ourselves for the year and opportunities to come when we report earnings in March.” The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process. About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement. Contact: investors@sanuwave.com